Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Accumulated Expenses (2024 - 2026)

Rapport Therapeutics (RAPP) has 3 years of Accumulated Expenses data on record, last reported at $4.0 million in Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 35.28% to $4.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.0 million, a 35.28% decrease, with the full-year FY2025 number at $7.1 million, up 17.18% from a year prior.
  • Accumulated Expenses reached $4.0 million in Q1 2026 per RAPP's latest filing, down from $7.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for RAPP hit a ceiling of $8.6 million in Q3 2025 and a floor of $1.8 million in Q2 2024.
  • A 3-year average of $5.3 million and a median of $6.1 million in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 73.92% in 2025, then plummeted 35.28% in 2026.
  • Tracing RAPP's Accumulated Expenses over 3 years: stood at $6.1 million in 2024, then rose by 17.18% to $7.1 million in 2025, then plummeted by 43.31% to $4.0 million in 2026.
  • Business Quant data shows Accumulated Expenses for RAPP at $4.0 million in Q1 2026, $7.1 million in Q4 2025, and $8.6 million in Q3 2025.